Trastuzumab Deruxtecan in HER2-Low Breast Cancer

被引：5
|
作者：
Schnog, John-John B. [1 ]
Samson, Michael J. [1 ]
Duits, Ashley J. [1 ]
机构：
[1] Curacao Med Ctr, Willemstad, Curacao
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 12期
关键词：
D O I：
10.1056/NEJMc2210368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1143 / 1144
页数：2
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Xiaolu
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
    Hurvitz, Sara
    Bardia, Aditya
    Tetef, Merry L.
    McAndrew, Nicholas P.
    Applebaum, Steven
    Master, Aashini K.
    DiNome, Maggie L.
    Lee, Minna K.
    Kirimis, Evangelia
    Kim, David D.
    Wang, Lisa S.
    Greene, Kyle
    Vu Phan
    Abdulla, Nihal
    Chan, David
    Spring, Laura M.
    Kivork, Christine
    Chauv, James
    CANCER RESEARCH, 2022, 82 (04)
  • [43] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
    Modi, S.
    Tsurutani, J.
    Tamura, K.
    Park, H.
    Sagara, Y.
    Murthy, R.
    Iwata, H.
    Krop, I. E.
    Doi, T.
    Redfern, C.
    Moreno-Aspitia, A.
    Redman, R.
    Lee, C.
    Sugihara, M.
    Fujisaki, Y.
    Takahashi, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
    Marhold, Maximilian
    Batista, Marta Vaz
    Blancas, Isabel
    Morales, Cristina
    Saura-Manich, Cristina
    Saavedra, Cristina
    Ruiz-Borrego, Manuel
    Cortez, Patricia
    Slebe, Felipe
    Campolier, Marta
    Santos, Juliana Carvalho
    Guerrero-Martinez, Jose Antonio
    Jimenez-Cortegana, Carlos
    Rottenmanner, Beate
    Forstner, Heidrun
    Bartsch, Rupert
    Preusser, Matthias
    FUTURE ONCOLOGY, 2025,
  • [45] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez-Castedo, Patricia
    Racca, Fabriccio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez, Adela
    Fernandez-Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [48] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [49] The Real-World Clinical Outcomes of Heavily Pretreated HER2+and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
    Lazaratos, Anna-Maria
    Dankner, Matthew
    Hamouda, Aalya
    Labidi, Soumaya
    Cohen, Victor
    Panasci, Lawrence
    Friedmann, Jennifer E.
    Patenaude, Francois
    Ferrario, Cristiano
    Basik, Mark
    Rose, April A. N.
    Fallah, Parvaneh
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [50] crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
    Zou, Yutian
    Yang, Anli
    Chen, Bo
    Deng, Xinpei
    Xie, Jindong
    Dai, Danian
    Zhang, Jinhui
    Tang, Hailin
    Wu, Tao
    Zhou, Zhigang
    Xie, Xiaoming
    Wang, Jin
    DRUG RESISTANCE UPDATES, 2024, 77
12345